ZL-24

N/A

Report date: 2025/01/26 15:59:43
NME

Base Information

Drug NameZL-24
Drug Alias NameRIPK 1/2 inhibitor (Chengdu Zeling Biomedical Technology)ZL-24
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor-interacting serine/threonine-protein kinase 1 inhibitorsSerine/threonine-protein kinase RIPK2 inhibitors
TargetsSerine/threonine-protein kinase RIPK2Receptor-interacting serine/threonine-protein kinase 1
Therapy Area/IndicationsMultiple SclerosisSepsis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChengdu Zenitar Biomedical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChengdu Zenitar Biomedical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple SclerosisSepsis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A